Speak directly to the analyst to clarify any post sales queries you may have.
The oligonucleotide synthesis market is rapidly evolving, driven by next-generation technologies, advanced biomanufacturing platforms, and renewed investment in precision medicine solutions. Senior executives in pharmaceuticals, biotechnology, and diagnostics are navigating an increasingly complex landscape as innovation, regulation, and supply chain dynamics intersect.
Market Snapshot: Oligonucleotide Synthesis Market Size and Growth
The Oligonucleotide Synthesis Market grew from USD 8.81 billion in 2024 to USD 10.28 billion in 2025. With a projected CAGR of 17.34%, the market is poised to reach USD 31.69 billion by 2032. This segment’s momentum reflects both longstanding research applications and a surge in demand from the expanding fields of diagnostics and gene-based therapeutics.
Comprehensive Scope & Segmentation of the Oligonucleotide Synthesis Market
This report offers a detailed look at the primary product, technology, and end-market segments influencing growth and adoption:
- Product Type: Equipment and instruments including DNA/RNA synthesizers and microarray synthesizers; reagents and consumables such as enzymes, labeling reagents, purification reagents, and synthesis reagents; software and service offerings encompassing bioinformatics tools, cloud-based data management, custom oligo synthesis, and data analysis platforms; synthesized DNA and RNA oligonucleotides.
- Synthesis Scale: Custom oligonucleotide synthesis and large-scale commercial manufacturing.
- Delivery Method: Enzymatic synthesis and solid-phase synthesis options supporting a variety of operational needs.
- Application: Diagnostics (including biosensors, molecular imaging, PCR, sequencing), drug discovery and development (lead optimization, target validation), research (functional genomics, gene expression, gene synthesis), and therapeutics (antisense therapy, CRISPR-based approaches, RNA interference).
- End-User: Academic and research institutes, contract research organizations, diagnostic laboratories, pharmaceutical, and biotechnology companies, each demanding tailored instruments, workflow support, and consumables.
- Regional Coverage: Americas (North America, Latin America), Europe, Middle East & Africa (Europe, Middle East, Africa), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan).
Technology integration across bioinformatics, advanced chemistry, automation, and cloud-based management is shaping productivity, reliability, and accessibility throughout the value chain.
Key Takeaways for Senior Decision-Makers
- Technological innovation is increasing yield and sequence complexity, supporting emerging needs in drug development, gene editing, and diagnostic platforms.
- Automated, high-throughput synthesizers and advanced bioinformatics are compressing delivery timelines, enabling more agile R&D and product cycles in life sciences.
- Demand for customized and large-scale oligonucleotide synthesis is rising, driven by both academic research and the rapid expansion of precision therapeutics.
- Sustainability initiatives are gaining traction, with greener chemistries, minimized hazardous waste, and circular economy approaches becoming operational imperatives.
- Regulatory changes and tariff measures are prompting greater supply chain diversification, nearshoring initiatives, and strategic partnerships to maintain resilience and manage risk.
- Collaborative ventures among academic, commercial, and manufacturing entities are streamlining innovation and accelerating access to bespoke synthesis solutions.
Tariff Impact: Navigating United States Supply Chain Disruptions
The implementation of 2025 United States tariffs has introduced new cost pressures throughout the oligonucleotide synthesis supply chain, particularly in procurement of phosphoramidites and enzymes. This climate is prompting market leaders to rethink sourcing strategies, accelerate regional facility investments, and forge supplier partnerships to manage volatility and support uninterrupted production across regions.
Methodology & Data Sources
This report employs a dual approach, combining in-depth secondary research—drawing on peer-reviewed journals, regulatory filings, patents, and industry white papers—with primary insights from interviews with executives, technical experts, and opinion leaders in the sector. Data triangulation and validation steps are integrated throughout to ensure accuracy and comprehensive market understanding.
Why This Report Matters to Strategic Leaders
- Informs procurement, investment, and partnership decisions with granular segmentation and actionable insights across key product and application areas.
- Supports risk management and growth planning by clarifying the impact of regulatory shifts and supply chain developments around the globe.
- Enables early identification of emerging technology and market trends, equipping leaders to respond to changing customer needs across regions and verticals.
Conclusion
The oligonucleotide synthesis market is experiencing multi-dimensional change, shaped by science, supply chain evolution, and market demand. Senior stakeholders can leverage this report to guide technology adoption, operational planning, and global expansion strategies with confidence.
Additional Product Information:
- Purchase of this report includes 1 year online access with quarterly updates.
- This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
Table of Contents
3. Executive Summary
4. Market Overview
7. Cumulative Impact of Artificial Intelligence 2025
Companies Mentioned
The companies profiled in this Oligonucleotide Synthesis market report include:- Agilent Technologies, Inc.
- Ajinomoto Bio-Pharma Services
- Bio-synthesis Inc.
- LGC Genomics Limited
- Danaher Corporation
- Eurofins Genomics LLC
- Eurogentec S.A. by Kaneka Corporation
- GE HealthCare Technologies Inc.
- Genscript Corporation
- Merck KGaA
- Nitto Denko Avecia Inc.
- Thermo Fisher Scientific Inc.
- Maravai Intermediate Holdings, LLC
- Biolegio B.V.
- Biolytic Lab Performance Inc.
- Microsynth AG
- parent added
- PerkinElmer, Inc.
- TAG Copenhagen A/S
- Generi Biotech
- Biocomma Ltd.
- Hongene Biotech Corp.
- TCI Chemicals (India) Pvt. Ltd.
- Creative Biogene
- Cusabio Technology LLC
- Synbio Technologies
- REPROCELL Inc.
- Bon Opus Biosciences, LLC
- Novartis AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 182 |
| Published | November 2025 |
| Forecast Period | 2025 - 2032 |
| Estimated Market Value ( USD | $ 10.28 Billion |
| Forecasted Market Value ( USD | $ 31.69 Billion |
| Compound Annual Growth Rate | 17.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |


